tradingkey.logo
tradingkey.logo
Suchen

AVITA Medical Inc

RCEL
Zur Watchlist hinzufügen
5.060USD
+0.390+8.35%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
778.65MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über AVITA Medical Inc Unternehmen

AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.

AVITA Medical Inc Informationen

BörsenkürzelRCEL
Name des UnternehmensAVITA Medical Inc
IPO-datumMar 18, 2012
CEOVance (Cary G)
Anzahl der mitarbeiter260
WertpapierartOrdinary Share
GeschäftsjahresendeMar 18
Addresse28159 Avenue Stanford
StadtVALENCIA
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl91355
Telefon16613679170
Websitehttps://www.avitamedical.com/
BörsenkürzelRCEL
IPO-datumMar 18, 2012
CEOVance (Cary G)

Führungskräfte von AVITA Medical Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Prof. Suzanne Crowe
Prof. Suzanne Crowe
Independent Non-Executive Director
Independent Non-Executive Director
46.93K
-6.37%
Mr. Jeremy Curnock Cook
Mr. Jeremy Curnock Cook
Independent Non-Executive Director
Independent Non-Executive Director
39.84K
-7.51%
Ms. Jan Stern Reed
Ms. Jan Stern Reed
Non-Executive Lead Independent Director
Non-Executive Lead Independent Director
--
--
Mr. Cary G. Vance
Mr. Cary G. Vance
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. Robert E. Mcnamara
Mr. Robert E. Mcnamara
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. David O'Toole
Mr. David O'Toole
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jessica Ekeberg
Ms. Jessica Ekeberg
Director - Investor Relations
Director - Investor Relations
--
--
Ms. Nicole Linda Kelsey, J.D.
Ms. Nicole Linda Kelsey, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
--
--
Dr. Michael Tarnoff Tarnoff, M.D.
Dr. Michael Tarnoff Tarnoff, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Prof. Suzanne Crowe
Prof. Suzanne Crowe
Independent Non-Executive Director
Independent Non-Executive Director
46.93K
-6.37%
Mr. Jeremy Curnock Cook
Mr. Jeremy Curnock Cook
Independent Non-Executive Director
Independent Non-Executive Director
39.84K
-7.51%
Ms. Jan Stern Reed
Ms. Jan Stern Reed
Non-Executive Lead Independent Director
Non-Executive Lead Independent Director
--
--
Mr. Cary G. Vance
Mr. Cary G. Vance
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. Robert E. Mcnamara
Mr. Robert E. Mcnamara
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. David O'Toole
Mr. David O'Toole
Chief Financial Officer
Chief Financial Officer
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von AVITA Medical Inc?

Die fünf größten Anteilseigner von AVITA Medical Inc sind: Prof. Suzanne Crowe

Wie viele Institutionen halten Anteile an AVITA Medical Inc (RCEL)?

Mit Stand vom 2026Q1 halten 209 Institutionen Anteile an AVITA Medical Inc, mit einem Gesamtmarktwert von etwa 6.52M, was 21.20% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1392153.00 gestiegen.